Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 1

3(50.0%)

6Total

Phase 2(3)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01042379Phase 2Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Role: lead

NCT06075953Phase 2Recruiting

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Role: lead

NCT04488081Phase 2Active Not Recruiting

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Role: lead

NCT05868226Phase 1Recruiting

PRE-I-SPY Phase I/Ib Oncology Platform Program

Role: lead

NCT04602117Phase 1Withdrawn

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Role: lead

NCT02358200Phase 1Terminated

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

Role: collaborator

All 6 trials loaded